In a patient with bladder cancer who has undergone transurethral resection of bladder tumor (TURBT) and now has PET imaging showing hypermetabolic lymphadenopathy in the retrocrural, retroperitoneal, and right iliac chain regions suggestive of nodal metastasis, what is the recommended next step in management?

Management of PET-Detected Nodal Metastases After TURBT

This patient requires histologic confirmation of the PET-positive lymph nodes followed by systemic platinum-based chemotherapy if metastatic disease is confirmed, as PET/CT has limited specificity for nodal staging in bladder cancer and tissue diagnosis is essential before initiating treatment for metastatic disease. 1

Immediate Next Steps

1. Tissue Confirmation is Mandatory

• PET/CT shows low specificity for lymph node staging in bladder cancer despite superior sensitivity compared to conventional CT. 2 False-positive uptake from inflammatory nodes is common, making histologic confirmation essential before committing to systemic therapy.

• Biopsy of the most accessible hypermetabolic node should be obtained through CT-guided percutaneous biopsy (retroperitoneal or iliac nodes) or laparoscopic/open biopsy if percutaneous approach is not feasible. 1

• The retrocrural location is particularly concerning as it represents distant nodal spread (M1 disease), which fundamentally changes prognosis and treatment approach compared to regional pelvic nodal disease. 1

2. Complete Staging Work-Up

While awaiting biopsy results, complete the metastatic evaluation:

• CT chest to evaluate for pulmonary metastases (mandatory in all patients with suspected metastatic disease). 1

• Bone scan if alkaline phosphatase is elevated or patient has bone pain, as bone metastases alter treatment planning. 3

• Laboratory assessment including complete blood count, comprehensive metabolic panel with liver function tests, and creatinine clearance to determine cisplatin eligibility (requires GFR ≥60 mL/min). 4

3. Cystoscopic Re-evaluation

• Repeat cystoscopy with bimanual examination under anesthesia to assess for residual bladder tumor, upstaging to muscle-invasive disease, or extravesical extension that may have been missed on initial TURBT. 1, 5

• If muscle was not present in the original TURBT specimen, 49% of patients will be understaged versus only 14% if muscle was present, making repeat resection critical. 1

Treatment Algorithm Based on Biopsy Results

If Biopsy Confirms Metastatic Urothelial Carcinoma:

• Platinum-based combination chemotherapy is the standard first-line treatment for metastatic bladder cancer. 1

• Cisplatin-based regimens (gemcitabine-cisplatin or dose-dense MVAC) are preferred if creatinine clearance ≥60 mL/min and no contraindications (neuropathy, hearing loss, heart failure). 1

• Carboplatin-based regimens (gemcitabine-carboplatin) are used for cisplatin-ineligible patients, though with lower response rates. 1

• Enfortumab vedotin plus pembrolizumab has recently emerged as a highly effective first-line option, showing superior survival compared to platinum chemotherapy in the metastatic setting, and should be strongly considered especially if cisplatin-ineligible. 6, 7

If Biopsy is Negative or Shows Only Reactive Changes:

• Proceed with risk-appropriate management of the bladder tumor based on original TURBT pathology (stage, grade, presence of muscle invasion). 1, 5

• Continue close surveillance with repeat PET/CT in 3 months to monitor the hypermetabolic nodes, as some may represent inflammatory changes that resolve. 2

Critical Pitfalls to Avoid

• Do not initiate systemic chemotherapy based on PET findings alone without tissue confirmation. The morbidity of platinum chemotherapy is substantial, and false-positive PET uptake would expose the patient to unnecessary toxicity. 1, 2

• Do not assume all hypermetabolic nodes represent metastatic disease. Inflammatory adenopathy from recent TURBT, urinary tract infection, or BCG therapy (if given) can cause false-positive PET uptake. 2

• Retrocrural nodes represent M1 disease (distant metastases), not N+ disease, which has significantly worse prognosis than pelvic nodal involvement alone and requires systemic rather than locoregional treatment. 1

• If variant histology (micropapillary, plasmacytoid, nested, sarcomatoid) was present on TURBT, this increases the likelihood that PET-positive nodes are truly metastatic and may warrant more aggressive upfront therapy. 1, 4

Multidisciplinary Discussion

• Convene genitourinary tumor board including urologic oncology, medical oncology, and interventional radiology to determine optimal biopsy approach and treatment sequencing. 4

• If metastatic disease is confirmed, discuss clinical trial eligibility for novel agents or combinations, as the treatment landscape for metastatic bladder cancer is rapidly evolving with ADC-immunotherapy combinations. 6, 7